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11b-Hydroxysteroid dehydrogenase 1 (11b-HSD1; EC 1.1.1.146) generates active glucocorticoid hor-
mones. Small molecule inhibitors have been developed to target 11b-HSD1 for the treatment of demen-
tia; these must enter brain subregions, such as the hippocampus, to be effective. We previously reported
mass spectrometry imaging measurement of murine tissue steroids, and deuterated steroid tracer infu-
sion quantification of 11b-HSD1 turnover in humans. Here, these tools are combined to assess tissue
pharmacokinetics and pharmacodynamics of an 11b-HSD1 inhibitor that accesses the brain.
[9,11,12,12-2H]4-Cortisol was infused (1.75 mg/day) by minipump for 2 days into C57Bl6 mice (male,
age 12 weeks, n = 3/group) after which an 11b-HSD1 inhibitor (UE2316) was administered (25 mg/kg oral
gavage) and animals culled immediately or 1, 2 and 4 h post-dosing. Mice with global genetic disruption
of Hsd11B1 were studied similarly. Turnover of d4-cortisol to d3-cortisone (by loss of the 11-deuterium)
and regeneration of d3-cortisol (by 11b-HSD1-mediated reduction) were assessed in plasma, liver and
brain using matrix assisted laser desorption ionization coupled to Fourier transform cyclotron resonance
mass spectrometry.
The tracer d4-cortisol was detected in liver and brain following a two day infusion. Turnover to
d3-cortisone and on to d3-cortisol was slower in brain than liver. In contrast, d3-cortisol was not
detected in mice lacking 11b-HSD1. UE2316 impaired d3-cortisol generation measured in whole body
(assessed in plasma; 53.1% suppression in rate of appearance in d3-cortisol), liver and brain.
Differential inhibition in brain regions was observed; active glucocorticoids were suppressed to a greater
in extent hippocampus or cortex than in amygdala.
These data confirm that the contribution of 11b-HSD1 to the tissue glucocorticoid pool, and the conse-
quences of enzyme inhibition on active glucocorticoid concentrations, are substantial, including in the
brain. They further demonstrate the value of mass spectrometry imaging in pharmacokinetic and
pharmacodynamic studies.
 2017 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction The reductase activity of 11b-hydroxysteroid dehydrogenase typeGlucocorticoids act in many tissues and when present in excess
can induce obesity, hyperglycaemia, and cognitive dysfunction.1 (11b-HSD1; EC 1.1.1.146) regenerates active glucocorticoid from
inert keto-steroid substrates in glucocorticoid target tissues
including liver, adipose tissue and brain. Whole body genetic dis-
ruption of 11b-HSD1 protects against the adverse systemic effects
of high-fat diet, e.g. improving lipoprotein profile and glucose tol-
erance and attenuating weight gain, compared with wild-type
mice [1]. Moreover, 11b-HSD1-deficient mice are protected against
age-related cognitive decline, further substantiating the notion
that reducing levels of glucocorticoids in tissues is of potential
therapeutic benefit [2,3].
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exposure to glucocorticoids in diseases such as Type 2 diabetes
mellitus and Alzheimer’s disease [4]. However, the efficacy of
11b-HSD1 inhibitors in patients has been modest and inconsistent.
In patients with type 2 diabetes mellitus, several 11b-HSD1 inhibi-
tors displayed only moderate effects to improve glycaemic control
[5–8]. While debate still exists over whether 11b-HSD1 inhibitors
have been tested in the correct populations [9], their clinical devel-
opment as therapies for metabolic disease has largely been discon-
tinued. In patients with Alzheimer’s disease, one study reported
lack of efficacy of an 11b-HSD1 inhibitor but the data supporting
pharmacodynamic engagement of the target in brain with this
compound are contentious [10]. To justify progression of further
candidate molecules for the treatment of dementia, such as
UE2343 (Xanamem) [11], it would be important to demonstrate
that 11b-HSD1 contributes substantially to glucocorticoid regener-
ation in relevant tissues in vivo, and that 11b-HSD1 inhibitors have
pharmacodynamic effects in these tissues and brain sub-regions.
Pharmacodynamic assessment of 11b-HSD1 is challenging since
circulating steroid concentrations do not reflect the local tissue
levels. Although active glucocorticoid levels may be decreased in
tissue following 11b-HSD1 inhibition, circulating levels are normal-
ized by feedback control of the hypothalamic-pituitary-adrenal
axis; this is a recognised response to enhanced cortisol clearance
following inhibition of cortisol regeneration in humans, evident in
compensatory increases in ACTH levels and circulating adrenal
androgens [5–8,11,12]. Moreover, within the tissue pool of active
endogenous steroid it is impossible to distinguish the proportion
derived from the plasma pool from that regenerated intracellularly
by 11b-HSD1. To address this in man we have developed an
approach to trace steroid regeneration by 11b-reductase using
stable-isotope labelled [9,11,12,12-2H]4-cortisol (d4F) [13]. d4F is
converted to d3-cortisone (d3E) in vivo by loss of the 11-
deuterium, providing a substrate for 11b-reductase to form d3F.
The rate of formation of d3F reflects the reductase activity of 11b-
HSD1, independently of adrenal synthesis. This approach has been
used to quantify 11b-reductase activity in response to metabolic
changes [14,15], diet [16–18] and pharmaceutical agents [9] inman.
Access of drugs to tissues is commonly quantified by auto-
radiography or by mass spectrometry. Auto-radiography has inher-
ent non-specificity as the active drug cannot be distinguished from
its radio-labelled metabolites. Measurement in tissue homoge-
nates by mass spectrometry overcomes this problem, but lacks
histological localisation. Mass spectrometry imaging (MSI) is
increasingly being deployed as an alternative approach, albeit not
for absolute quantitation [19]. It offers the advantages of simulta-
neously identifying both drug and metabolites in tissues while pro-
viding a fingerprint of pharmacodynamic changes in the
metabolome of responsive organs [19]. Recently, we developed a
novel approach to quantify steroid substrate and product ratios
of 11b-HSD1 metabolites using MSI following steroid derivatiza-
tion on tissue [20]. Here we report the combined application of
stable-isotope tracer infusion with MSI to understand the pharma-
codynamic responses to a pre-clinical tool molecule acting as a
brain-penetrant 11b-HSD1 inhibitor, UE2316 [21–25], and demon-
strate how these measurements can complement conventional
measures of 11b-HSD1 activity ex vivo.2. Materials and methods
2.1. Materials
[9,11,12,12-2H]4-Cortisol (d4F), [9,12,12-2H]3-cortisol (d3F) and
internal standard [2,2,4,6,6,7,21,21-2H]8-corticosterone were from
Cambridge Isotopes, MA, USA. Unlabeled steroids were fromSteraloids Inc, PA, USA. Solvents were glass-distilled HPLC
grade (Fisher Scientific, Loughborough, UK). UE2316, [4-(2-
chlorophenyl)-4-fluoro-1-piperidinyl][5-(1H-pyrazol-4-yl)-3-thienyl]-
methanone and UE2346 [26] were synthesized by High Force Ltd,
Durham, UK [11]. Other chemicals were from Sigma-Aldrich
(Dorset, UK) unless stated. Room temperature (RT) was 18–21 C.
2.2. Animals and biomatrix collection
C57BL/6 mice (Harlan Olac Ltd, Bicester, UK) were studied
under UK Home Office license. Groups of C57Bl/6 mice
(n = 3/group, male, 12 weeks) were infused with d4F (1.75 mg/day,
at a rate of 1.03 mL/h by surgically implanted sub-cutaneous mini-
osmotic pumps, primed as per manufacturer instructions; ALZET
model 1003, Cupertino, CA, USA) or vehicle (dimethylsulfoxide
(DMSO): propylene glycol (PG) (50:50)). After 48 h mice were trea-
ted with UE2316 (11b-HSD1 inhibitor; 25 mg/kg oral gavage) or
vehicle (2% DMSO, 38% PEG, 60% saline (0.9%), 5 mL/kg) and culled
immediately or 1, 2 or 4 h post-dosing. Mice with genetic disrup-
tion of Hsd11b1 (KO; male, 8–12 weeks [27] bred in-house on a
C57Bl/6 genetic background) or C57Bl/6 controls were infused sim-
ilarly with d4F or vehicle for 48 h.
Animals were killed by decapitation, plasma was prepared from
trunk blood (collected in EDTA coated tubes) and tissues were
snap-frozen in liquid nitrogen and stored at 80 C.
2.3. MALDI-MS instrumentation and MS parameters
MSI was performed adapting the method described [20], using a
12T SolariX MALDI-FT-ICR-MS (Bruker Daltonics, MA, US) and
employing a Smartbeam 1 kHz laser, operated with SolariX control
v1.5.0 (build 42.8), Hystar 3.4 (build 8) and FlexImaging v3.0 (build
42).
The Girard T (GirT) derivative of d8-corticosterone (m/z
468.36718) was detected as before [20], but in CASITM full mass
(broadband) mode using an isolation window at 470 ± 25 Da in
profiling mode, affording a 10–50-fold increase in sensitivity. The
quasimolecular ion of UE2316 was monitored at +ve m/z
390.08377 and where appropriate, normalized to the matrix ion
of a-cyano-4-hydroxycinnamic acid, +ve m/z 417.04834 Da. On-
tissue spectral characterisation of the steroid tracers was per-
formed by manual spotting (5 ng, 10 mg/mL; methanol: water
(1:1) of d4F and d3F onto a control tissue section (murine brain).
Ions were isolated atm/z 470.3 ± 20 Da for 30 s yielding a 2 Mword
time-domain transient. The ions monitored for d4F-GirT and d3F-
GirT were m/z 480.33696 and 479.33066 Da respectively. Struc-
tural confirmation of ions of GirT-d4F and GirT-d3F was assessed
using LESA-nanoESI-FT-ICR-MS (Advion Tri-versa Nanomate)
[20]. All analyses were carried out using 800 laser shots.
2.4. Quantitative analysis of UE2316
UE2316 was extracted from plasma (150 mL) enriched with
internal standard, UE2346 (50 ng), into ethyl acetate (3  1.5 m
L). The solutions were shaken (15 min) and, following centrifuga-
tion (3500g, 50 min, 4 C), the organic extracts were dried under
oxygen free nitrogen (OFN) at RT. Calibration curves were
extracted from control plasma in the range 10–10,000 nM.
UE2316 was extracted from liver and whole brain (150 mg,
enriched with UE2346 (100 ng)) as previously described for brain
([20] Supplementary Information).
2.5. Metabolite identification
Metabolite identification was performed using a LESA-nanoESI
coupled to FTICR-MS. Ions were isolated at 406.08 Da (±5) m/z
90 D.F. Cobice et al. / Biochemical Pharmacology 148 (2018) 88–99(Metabolite III) and 404.06 Da (±5) (Metabolite IV) for 35 s yielding
a 2 Mword time-domain transient and CE of 33 V was applied for
CID experiments.
2.6. Analysis of corticosteroids in plasma and tissue extracts
2.6.1. Plasma
Plasma analysis was performed as described previously [14].
Plasma d3E, d4F and d3F were quantified by LC/MS-MS. Epi-
cortisol (10 ng) was added to 50 lL plasma and extracted using
chloroform (0.5 mL). Solvent was evaporated and then reconsti-
tuted in mobile phase (95% water and 5% acetonitrile with 0.1% for-
mic acid) before injection into an Acquity UHPLC (Waters,
Manchester, UK) interfaced with a QTrap 5500 (Sciex, Warrington,
UK) using a Sunfire C18 column (100 mm  2.1 mm  3.5 lm;
Thames Restek, High Wycombe, UK, with column temperature
25 C and mobile phase flow rate 0.5 mL/min). A gradient was
employed between 10 and 20 min achieving 5% water and 95% ace-
tonitrile. Ionization was achieved by positive electrospray. MS
Source conditions were as follows: collision gas medium, ion spray
voltage 5500 V, temperature 500 C and curtain gas, GS1 and GS2
all 40 psi). The precursor and product m/z and MS parameters
(declustering potential, collision energy, collision exit potential;
V) were as follows: epi-cortisol (363? 121; 131, 29, 14), d3F (36
6? 121; 121, 27, 20), d4F (367? 121; 121, 25, 20), corticosterone
(347? 121; 66, 69, 8), and d3E (364? 77; 42 eV; 131, 29, 14).
Compounds were quantified by the ratio of area under peak of
interest to area under peak of internal standard against a standard
curve (0.1–50 ng). In the absence of a commercial standard, d3E
was calibrated against d4F.
2.6.2. Liver
Murine liver (300 mg) was homogenised in methanol–acetic
acid (100:1 v/v, 10 mL) using a mechanical homogeniser and
assisted by ultrasonication and enriched with internal standard,
d8-corticosterone (5 ng). The supernatant was retained and the
pellet formed followed centrifugation (5000g, 10 min, 4 C), fur-
ther extracted with methanol–acetic acid (100:1 v/v, 10 mL) and
the supernatants combined and dried under oxygen free nitrogen
(OFN) at RT. Residues were heated (40 C, 60 min) with Gir T
reagent (5 mg/mL in methanol with 0.2% trifluoroacetic acid; 10
mL) in an oven or water bath then allowed to cool at RT, mixed with
a-cyano-4-hydroxycinnamic acid (CHCA; 10 mL; 10 mg/mL) in ace-
tonitrile (80% + 0.2% v/v TFA) and analysed by MALDI-FTICR-MS as
per 2.3, using an isolation window of 470.3 ± 50 Da.
2.6.3. Whole brain
Steroids were extracted from whole brain as previously
reported [20]. The residue was evaporated and derivatised as for
liver (Section 2.6.2) and MALDI-FTICR-MS conducted as above
(Section 2.3).
2.7. Tissue imaging of steroids in brain sections by MSI
2.7.1. Tissue preparation for MS imaging
Brains were embedded in gelatin (50% w/v) and cryosections
(10 mm) thaw mounted onto conductive indium tin-oxide (ITO)-
coated glass slides (Bruker Daltonics, Bremen, GmbH), stored in a
vacuum desiccator (RT, 1 h) and then at -80 C. Adjacent sections
were stained using haematoxylin and eosin. After fixation in cold
acetone, tissue sections were examined using an optical micro-
scope (40, Leica Microsystems Inc, Bannockburn, IL, USA) with
CCD camera (Hitachi, 3969, Japan). Internal standard, derivatiza-
tion reagents and matrix were applied manually as described pre-
viously [20].2.7.2. Structural confirmation of GirT-d4F and GirT-d3F in a brain
using LESA-nanoESI-FTIRMS
Brain sections were subject to derivatization with Gir T and
then analysed immediately using LESA-nanoESI-FT-ICR-MS [20].
Ions were isolated atm/z 470.3 ± 20 Da for 30 s yielding a 2 Mword
time-domain transient. CID fragmentation was carried out at 28 eV
and CID spectra recorded.
2.8. Data analysis
For tissue homogenates, the average spectral intensities of the
corresponding GirT-d4F, GirT-d3E, GirT-d3F and GirT-d8-corticosterone
ions were presented as ratios of d4F/d3F, d4F/d8-corticosterone,
d3F/d8-corticosterone and d3E/d8-corticosterone. The amount of
internal standard (d8-corticosterone) was normalized (per mg tis-
sue) across different tissues, to allow inter-tissue comparison. In
MS images the average spectral intensities of GirT-d4F, GirT-d3E
and GirT-d3F in regions of interest (ROIs) across the cortex,
hippocampus and amygdala were presented similarly. An average
value was calculated based on the weighted average. The intensi-
ties of GirT derivatives of deuterated steroids were corrected for
any potential monoisotopic contribution of naturally occurring
deuterium, assessed using standards. The rate of whole body
appearance of d3F was calculated by dividing the infusion rate
by the tracer/tracee ratio (d4F/d3F). Data are expressed as mean
± SEM and differences were analysed using a one-way or two-
way ANOVA with Fisher’s LSD post hoc test and Mann-Whitney-
Wilcoxon’s or Student’s t-test as appropriate. Statistical
significance was accepted at p < 0.05. Signal to noise ratio is
denoted as S/N.3. Results
3.1. MS analysis of tracers
d4F and d3F reacted with Gir-T and were detected at m/z
480.33696 Da and m/z 479.33066 Da respectively, with good mass
accuracy (<10 ppm from their corresponding theoretical monoiso-
topic masses, m/z 480.33073 Da and m/z 479.33073 Da respec-
tively; Fig. 1A). Tracer steroids were detected with similar mass
accuracy when analysis of tissue from treated mice was performed
(Fig. 1B). Structural confirmation by fragmentation was achieved
using LESA-nanoESI-FT-ICR-MS, yielding fragmentation patterns
typical of GirT hydrazones (Fig. 1C)[20,28]. CID of the GirT deriva-
tives (Fig. 1D) generated fragment ions characteristic of pyrazole
derivatives formed by rearrangement of the derivatised group fol-
lowing loss of the quaternary amine tag [M59]+ and carbon
monoxide [M87]+. These are characterised by ions at m/z
421.26355, m/z 393.26847 (GirT-d4F) and m/z 420.25714, m/z
392.25714 (GirT-d3F), respectively.
A commercial standard for d3E was not available. However,
within tissues ions of m/z 477.32554 Da were detected within 5
ppm of the expected mass of the derivatised steroid in animals
treated with d4F and not in controls.
3.2. Turnover of d4F in mice with genetic disruption of Hsd11b1
The circulating concentrations of d4F were the same between
KO mice and controls, but d3E was approximately 3-fold higher
in the plasma of KO mice (Fig. 2A). d3F was not detected in KO
mice, but was present in controls, being generated with a rate of
appearance of 121 ± 13 nmol/h. Within tissues, d4F was readily
detected in liver and brain and amounts were not different
between KO and controls (Fig. 2B). d3E was present in higher
Fig. 1. (A) Representative MALDI-FTICR-MS of Girard T (GirT)-derivatives of deuterium labelled glucocorticoid standards d4 and d3-cortisol (d4F, d3F, 5 ng). Observed ions at
m/z 479.33066 Da for GirT-d3F and m/z 480.33696 Da for GirT-d4F. (B) Representative Mass spectrum of ions collated from murine brain from animals receiving d4-cortisol
infusion following derivatization, showing ions with anticipated mass for Girard T derivatives of d4 and d3-cortisol. (C) Mass spectra of Girard T (GirT) derivatives of
deuterium labelled cortisol tracers following liquid extraction surface analysis with nanoESI-FT-ICR collision induced dissociation (CID). CID mass spectra of precursors ions at
m/z 480.33711 Da (GirT-d4F) and 479.33074 Da (GirT-d3F) and (D) proposed fragmentation patterns are shown. Cell isolation was 20 s and collision energy was set to 28 eV.
cps: count per seconds.
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Fig. 2. (A) Concentrations of d4-cortisol (d4F) were not different (p = 0.07) in mice with genetic disruption of 11b-hydroxysteroid dehydrogenase 1 (11b-HSD1) (KO)
compared with their wild-type controls (WT). Concentrations of d3-cortisone (d3E) were higher in KO mice, whereas d3-cortisol (d3F) was not detected. Likewise (B)
amounts of d4F in liver and brain expressed as a ratio to internal standard (IS) was not altered by disruption of 11b-HSD1, but (C) amounts of d3E were increased. (D) The d4F/
d3F ratios were highest in plasma, lower in brain and even lower in liver (E) Mass spectrometry images of (i, iv) Girard T-d4F at m/z 480.33073 Da (ii, v) Girard T-d3E at m/z
477.29299 Da (iii, vi) Girard T-d3F at m/z 479.33073 Da in brains of WT and KO mice respectively, showing lack of regeneration of d3F following whole-body disruption of
11b-HSD1. Signal intensity is depicted by color on the scale shown. Scale bar (2 mm). Data are compared by Mann Whitney Wilcoxon, ***p < 0.001 and *p < 0.05.
92 D.F. Cobice et al. / Biochemical Pharmacology 148 (2018) 88–99amounts in the livers and brains of KO mice compared to those
from controls (Fig. 2C). The d4F/d3F ratio was lower in tissues than
in plasma and lower in liver than in brain (Fig. 2D). d3F was not
detected in any tissues in KO mice, as depicted in brain by MSI
in Fig. 2E(vi).3.3. Effects of a single dose of UE2316
3.3.1. Pharmacokinetic analysis of UE2316
UE2316 was detected in plasma of mice culled at all time points
1, 2 and 4 h post-dose, peaking at 2 h (Fig. 3A). UE2316 penetrated
Fig. 3. UE2316 levels in (A) plasma and (B) liver and brain in mice measured following a single oral dose. Drug levels reached a peak at 2 h post-dose (HPD) at all sites and
were declining by the 4 h time point. (C) Amounts of UE2316 were quantified relative to the matrix cluster ionm/z 417.04834 Da by mass spectrometry imaging. The highest
levels were found in hippocampus and all regions showed peak amounts at 2 h post-dose. Drug was not detected (ND) in brain regions of untreated animals. Statistical
analysis was performed using a one-way ANOVA with Bonferroni’s post hoc test. Data are mean ± SEM (n = 3). **p < 0.01 and *p < 0.05.
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declining at 4 h, although still detectable. The amounts in liver
exceeded those in brain, by approximately 2-fold at all time points.
(Fig. 3B). Similar time-courses were observed in brain sub-regions
(Fig. 3C), with highest levels of drug in hippocampus.3.3.2. MSI of UE2316 and its metabolites in tissues
Metabolites of UE2316 were identified in liver and brain from
mice 4 h post-dose after treatment with UE2316 and structures
proposed with mass accuracy calculation within 5 ppm of their
corresponding theoretical monoisotopic masses. Two potential
phase II metabolites were only observed in liver; Metabolite I
was proposed at m/z C25H27ClFN3O7S 569.13211 Da potentially
formed by N-glucuronidation and Metabolite II C24H25ClFN3O5S
with m/z 521.01143 Da was suggested as a further phase II
metabolite formed by further decarboxylation (Fig. 4A, with
images in Fig. 7A).
In both brain and liver, two further potential metabolites were
detected, with a fragment ion of m/z 177.01210 (C8H5N2OS; theo-
retical 177.01171). In the brain these had distinct spatial distribu-
tions. From the molecular structure of UE2316, it is anticipated
that the piperidine alpha hydrogens will be prone to oxidationby Phase I CYP450 enzymes leading to potential hydroxylation
and further oxidised ketone products (Fig. 4B) and fragmentation
occurred at the amide bond. The proposed hydroxylation product
at m/z 406.07868, Metabolite III (C19H18ClFN3O2S) (Fig. 4Cii) was
detected mainly distributed across the striatum and cortex. The
further oxidised metabolite at m/z 404.06303, Metabolite IV
(C19H16ClFN3O2S, possible ketone formation) (Fig. 4Ciii) was mainly
found in the hippocampus and amygdala. These metabolites were
in distinct locations depicted by lack of superimposition (Fig. 4Civ).3.3.3. Pharmacodynamic assessment of 11bHSD1 activity
The extent of inhibition of 11b-HSD1 by UE2316 with time was
assessed by tracer kinetics, measuring the enrichment of infused
tracer with newly generated d3F (d4F/d3F) and rate of appearance
(Ra) of d3F. Circulating d4F levels did not change (Fig. 5A) but accu-
mulation of d3E was observed 2 h after UE2316 administration
(Fig. 5B), with a concomitant reduction in circulating d3F
(Fig. 5C), increased d4F/d3F ratio (Fig. 5D), and a corresponding
53.1% reduction in whole-body Ra d3F (Fig. 5E). These effects
waned by 4 h. d4F tracer was detected in liver and whole brain
after 48 h infusion (Fig. 6A); amounts were higher in liver than
in brain. The increase in d4F/d3F ratio (indicative of enzyme
Fig. 4. Proposed metabolic pathway of UE2316 in (A) liver and (B) brain. Metabolites were detected in murine brain by mass spectrometry imaging 4 h following single dose
of UE2316. (C) Proposed Phase I metabolites had different distribution across brain, with metabolite III mainly distributed in the striatum (St) and cortex and metabolite IV
found in the hippocampus (HPC) and amygdala (Am). (i) Haematoxylin and eosin histological staining. Molecular distribution maps of (ii) Potential hydroxylation metabolite
(Metabolite III) at 406.07868 Da. (iii): Ketonic metabolite atm/z 404.06303 Da (Metabolite IV). (iv) Molecular superimposition maps of Metabolite III (blue) and Metabolite IV
(green) show metabolites in different locations within the brain. Scale bar (2 mm). HPC: hippocampus, Am: amygdala, St: Striatum. (For interpretation of the references to
color in this figure legend, the reader is referred to the web version of this article.)
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than in plasma (p = 0.01); at the 2 h time point the ratio was
increased approximately 2.3-fold in liver and 1.8-fold in brain
and 1.5-fold in plasma (Fig. 6D). In liver, the levels of d3F declined
(Fig. 6C) to a nadir 2 h post-UE2316, with accumulation of d3E
(Fig. 6B). This corresponded with a reduced rate of formation of
d3F, inferred from an increased d4F/d3F ratio (Fig. 6D). This effect
had started to diminish by 4 h. In brain, a similar effect was
observed 2 h post-UE2316 but inhibition was sustained until 4 h.
By MSI, d4F and its metabolites were observed within hip-
pocampus, cortex and amygdala (Fig. 7). Again UE2316 invoked
an increased in d3E and a decline in d3F which reached a maxi-
mum at 2 h post-dose and was sustained until 4 h. Corresponding
increases in the d4F/d3F ratio were observed which were statisti-
cally significant in the hippocampus and cortex.4. Discussion
Although the extensively documented consequences of genetic
and pharmacological manipulations of 11b-HSD1 in mice strongly
suggest that extra-adrenal regeneration of glucocorticoids is
important, the stable-isotope tracer data reported here provide
the first in vivo quantification of enzyme activity in tissues in
rodents. Moreover, although tracer kinetics have been used in
combination with arterio-venous sampling to quantify 11b-HSD1
turnover in humans, the data here provide the first information
about tracer kinetics within tissues and, notably, within brain
sub-regions. Finally, the data presented describe the tissue phar-
macokinetics and pharmacodynamic responses of a brain-
penetrant 11b-HSD1 inhibitor, confirming the potential for sub-
stantial effects on tissue glucocorticoid levels and illustrating the
Fig. 5. Concentrations of (A): d4-cortisol (d4F) (B) d3-cortisone (d3E) and (C) d3-cortisol (d3F) in plasma following a single dose of UE2316, an inhibitor of 11b-
hydroxysteroid dehydrogenase 1. D4F did not change during the 4 h time period but concentrations of d3E increased 2 h post-dose and those of d3F reduced. (D) The d4F/d3F
ratio increased again until 2 h reflected in a (E) reduced rate of appearance (Ra) of d3F, indicative of enzyme inhibition. Statistical analysis was performed using a one-way
ANOVA with Bonferroni’s post hoc test. Data are mean ± SEM (n = 3). *p < 0.05.
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and the consequent changes in tissue steroids.
Previous studies in rodent models have relied on measuring the
velocity of 11b-HSD1 in the presence of fixed substrate concentra-
tion ex vivo in tissue homogenates or slices. While this approach
reflects changes in absolute protein concentrations, it cannot be
extrapolated to infer the contribution of 11b-HSD1 to active tissues
steroids in vivo. Moreover, although irreversible inhibitors remain
bound in the active site of the enzyme during sample processing,
most 11b-HSD1 inhibitors in the development pipeline, including
UE2316, are reversible competitive inhibitors that may dissociate
in solution. Measurement of ratios of enzyme substrate and pro-
duct (predominantly 11-dehydrocorticosterone and corticosterone
in rodents, cortisone and cortisol in humans) may be more infor-
mative, including tissue or microdialysis samples from brain [21],
but cannot distinguish glucocorticoids derived from plasma or
from local regeneration and reflect only net balance, not turnover,between 11b-HSD1 and 11b-HSD2 activities. Use of stable-isotope
tracers in vivo can overcome these limitations.
In wild-type mice d4F was infused and readily detected in
plasma, along with its metabolites, d3E and d3F. Initial dose-
ranging studies were performed to design infusion rates to sup-
press the hypothalamic-pituitary-adrenal axis, replace adrenal
steroids and achieve steady-state circulating d4F concentrations
in mouse within the diurnal range of corticosterone. The infusion
rate per kg was 300 fold higher than used previously in the clinical
setting in man, achieving concentrations 40 higher than those
studied as human tracers. This suggests a more rapid rate of clear-
ance of glucocorticoids in the mouse than human, by around an
order of magnitude.
The calculated production rate of d3F in mice, at 120 nmol/h
or 4800 nmol/kg/h in a 25 g mouse, can then be compared with
values in humans of 3600 nmol/h or 50 nmol/kg/h in a 70 kg
man. The substantially higher rate (100 fold) of production in
Fig. 6. Amounts of (A) d4-cortisol (d4F) (B) d3-cortisone (d3E) and (C) d3-cortisol (d3F) in liver, and whole brain 4 h following a single dose of the 11b-hydroxysteroid
dehydrogenase 1 inhibitor, UE2316. (D) Regeneration of d3F, assessed by d4F/d3F ratio, was detected in liver and brain and was suppressed by the inhibitor. Inhibition was
sustained longer in brain than liver. Data are mean ± SEM (n = 3) and were compared by a one-way ANOVA with Bonferroni’s post hoc test. **p < 0.01 and *p < 0.05.
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tions, around the enzyme Km. These can only be estimated due to
lack of a commercial analytical standard, but can be extrapolated
from those of d4F as being around 40-fold higher in mice than in
humans. Thus it appears that the turnover of tracer to d3F by mur-
ine 11b-HSD1 displays similar kinetics between mouse and
human, perhaps 2-fold higher in mice, but proceeds in the face
of more rapid clearance of tracer by other routes.
In mice with disruption of Hsd11b1, d3F was not detected in
plasma or in any tissue tested, corroborating the notion that 11b-
HSD1 is the only enzyme able to reduce 11-keto-steroids in vivo
and supporting attenuated formation of the d3F product as an
index of pharmacological enzyme inhibition [13]. The levels of
d4F achieved in plasma during steady state infusion were the same
between wild-type and knockout animals or tended (p = 0.07) to be
higher in Hsd11b1 knockout mice. This may reflect a contribution
of dehydrogenase activity of 11b-HSD1 to d4F clearance or indeed
changes in other metabolic pathways in the knockout animals that
could be teased apart with larger numbers. Lack of reductase activ-
ity alone would not influence d4F levels. In humans impaired clear-
ance of glucocorticoids can be detected readily by tracer infusion,
seen following 11b-HSD1 inhibition with carbenoxolone [13], a
nonselective inhibitor which affects both reductase and dehydro-
genase activities. Previous studies of glucocorticoid clearance in
mice have generally utilised endogenous glucocorticoids, which
are subject to contributions from both oxidative and reductive
metabolism. Surprisingly Morgan et al. [29] reported no change
in circulating corticosterone concentrations following infusion of
the endogenous steroid in mice lacking Hsd11b1. This suggests thatin mice there may be substantial dehydrogenase as well as reduc-
tase activity of 11b-HSD1, which is not present in humans, and
these differences in 11b-HSD1 kinetics between mice and humans
may explain, at least in part, the inconsistencies between effects of
11b-HSD1 inhibitors in murine models and human patients [4,30].
Within tissues the highest amounts of tracer detected during
d4F infusion were in liver with less detected in brain. Likewise
d3E and d3F were easily detected in both tissues, but higher in
liver. Ion suppression will vary between tissues, but the intensity
of signal of internal standard was not substantially different
between liver and brain, suggesting a slower penetration into brain
than liver. In each tissue, d4F/d3F ratio was lower than in plasma,
consistent with local regeneration of d3F by 11b-HSD1, which was
absent in Hsd11b1 knockout mice. The most striking decrement in
tissue versus plasma d4F/d3F ratio was in murine liver, consistent
with human data suggesting liver is the major site of cortisol
regeneration [31–34]. Indeed it has been hard to quantify 11b-
HSD1 activity in human brain in vivo [32].
UE2316 is a brain-penetrant 11b-HSD1 inhibitor that is effica-
cious in preclinical models [24] and is chemically similar to
UE2343, a clinical development candidate [11] to treat Alzheimer’s
disease. It selectively inhibits the reductase activity of the enzyme.
After a single oral dose, UE2316 was detected rapidly in blood and
liver and also in brain, albeit in lower amounts, peaking at 2 h post-
dose. This is in keeping with rapid inhibition of enzyme activity
measured ex vivo in homogenates [24]. During the first 2 h, the
drug circulated in plasma at concentrations 10–20-fold in excess
of the IC50 (measured in stably-transfected cells) [24]. By utilising
MSI we have previously demonstrated that UE2316 accesses the
Fig. 7. Evaluation of changes in abundances of UE2316, d4-cortisol (d4F), d3-cortisone (d3E) and d3-cortisol (d3F) in brain regions following timed inhibition of 11b-
hydroxysteroid dehydrogenase 1 by UE2316, measured by mass spectrometry imaging in sections of murine brain. MS images of (A) UE2316 at m/z 390.08377, Girard T-d4F
at m/z 480.33073 Da, Girard T-d3E at m/z 477.29299 Da, Girard T-d3F at m/z 479.33073 Da, showing that overall signal intensity of the Girard T derivative of d3E increased
and that of d3F declined upon treatment with inhibitor. Signal of (C) Girard T-d4F (D) Girard T-d3E (E) Girard T-d3F were normalized to internal standard (IS) d8-
corticosterone within regions of interest, cortex, hippocampus (HPC) and amygdala (Am). The ratio of d4F/d3F increased in the cortex and hippocampus over the first 2 h
post-dosing (HPD) but not in the amygdala. This effect was sustained to 4 h, although the accumulation of d3E was less marked by 4 h compared with 2 h. Signal intensity is
depicted by color on the scale shown. Scale bar (2 mm). Data are mean ± SEM (n = 3) and were compared by a one-way ANOVA with Bonferroni’s post hoc test. *p < 0.05.
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were found in hippocampus. Here, we also detected specific
metabolites of UE2316 in liver and brain by MSI. Metabolism arose
from a mixture of Phase I and II reactions, however different
metabolites were abundant in specific subregions of brain, pre-
sumably related to the location of specific cytochrome P450
enzymes [35]. Access to this information has important benefits
for assessing potential for side-effects and for the duration of the
pharmacodynamics effect of the drug within regions of brain
important for cognition and memory, such as hippocampus and
cortex.
The combination of tracer steroid infusion with MALDI sam-
pling and MSI allowed the presence of UE2316 to be associated
with its pharmacodynamic consequences for regeneration of active
glucocorticoids. The d4F/d3F ratio in plasma doubled after UE2316
administration, corresponding to halving of whole body regenera-
tion of d3F. Amounts in deuterated tracer and metabolite levels in
tissue will in part reflect plasma, but the magnitude of change in
dilution of the d4F tracer with tracee (d3F) following administra-
tion of drug was greater in both liver and brain than plasma, con-
sistent with local enzyme inhibition. In brain, the extent of
inhibition of 11b-HSD1 was in keeping with previous studies, mea-
sured ex vivo in brain homogenates [24]. However, suppression of
glucocorticoid regeneration was sustained for longer in brain than
liver, despite a similar profile in amounts of drug with time. This
might reflect slower turnover of steroid within brain tissue. Within
the brain subtle differences in the extent of inhibition between
regions could also be seen. Inhibition of 11b-HSD1 by UE2316
was not detected in amygdala but was achieved in hippocampus
and cortex, regions with higher enzyme activity. Again this demon-
strates that regional-selective responses to drugs might be
assessed by the approach described here. The hippocampal region
is vitally important in age-related memory loss and its susceptibil-
ity to corticosteroid action is well established. Inhibition of 11b-
HSD1 in brain has previously been shown to be effective in slowing
disease progression in murine models of Alzheimer’s disease [24].
In summary, combined pharmacokinetic and pharmacodynam-
ics analysis using tracer infusion and MSI has shown that the turn-
over of 11b-HSD1 reductase activity in mice is rapid in vivo, and
occurs in liver and brain, whereas it is absent in Hsd11b1-
deficient mice and is measurably inhibited by UE2316. These
insights inform the extrapolation of results from mice to humans
and justify continued efforts to target 11b-HSD1 in the brain.
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